Maternal health among adolescents in low- and middle-income countries (LMICs) remains a largely unexplored and frequently neglected area within the public health field. Adolescent birth rates remain disproportionately high in LMICs, accounting for approximately 97% of all adolescent births globally. The prevalence of child marriage, poverty, gender-based violence, and limited access to and utilization of contraceptive methods all contribute to this startling statistic.

During humanitarian emergencies, women and newborns face severe disparities and heightened vulnerabilities, increasing their risk of illness and death. Humanitarian crises—caused by conflict, climate-related disasters, or forced displacement—disrupt health systems, limit access to essential services, and increase the likelihood of preventable deaths. In 2023, 58% of global maternal deaths, 50% of newborn deaths, and 51% of stillbirths worldwide occurred in the 29 countries with a UN humanitarian response plan or regional response plan. In humanitarian emergencies, a lack of skilled health personnel, inadequate infrastructure, and shortages of essential medicines are common—resulting in limited access to both basic and emergency maternal and newborn care. A fight for humanitarian aid is also a challenge, as maternal and newborn health are often under-prioritized or neglected in humanitarian response.

In South Korea, pet strollers have become more popular than baby strollers. Sales reports from an e-commerce firm in that country noted that sales of infant strollers fell by 43% in 2023, while the sales of pet strollers rose by 57%—and consumer demand for pet products continued to grow into the first months of 2024. There has also been an uptick in the opening of veterinary hospitals that is outpacing the establishment of pediatric clinics in many neighborhoods.

This article is adapted from “Pioneering Solutions: Climate Finance, Gender Equity, and Sexual and Reproductive Health Services”

A warming world is leading to new challenges for communities and countries around the globe. The significant impacts of climate change on global health, and on women and girls, are well-documented. Yet despite the evidence, funding for climate responses that focus on health or gender remains relatively low. In the rare instances where climate finance provides funds to improve health services, sexual and reproductive health (SRH) services—which are critical to women’s full participation in society and decisionmaking—are largely neglected.

Each day, almost 800 women die from preventable causes related to pregnancy and childbirth. A maternal death occurs every two minutes. Maternal mortality is defined as the death of a woman from complications of pregnancy or childbirth that occur during the pregnancy or within 6 weeks after the pregnancy ends.*

At the opening of the Commission on the Status of Women in New York this past March,  UN Secretary-General António Guterres underscored the importance of stepping up national and global efforts to advance the rights of women. Guterres observed that “many women and girls are also facing a war on their fundamental rights at home and in their communities. Hard-fought progress is being reversed.”

July 11 is World Population Day—designated annually by the United Nations as a focused opportunity to examine population trends and their implications for society. This year, World Population Day offers a chance to reflect on the 30^th anniversary of one of the largest and arguably most influential world population conferences in history—the 1994 International Conference on Population and Development (ICPD).

Last month, the biopharmaceutical company Gilead shared groundbreaking results from a recent clinical trial (PURPOSE1) for long-acting injectable HIV prevention. The twice-yearly injectable drug, lenacapavir, provided total protection from HIV for a test group of 2,134 women in Uganda and South Africa. While lenacapavir has been used to treat multi-drug resistant HIV since 2022, this trial marks the first usage as pre-exposure prophylaxis (PrEP). PrEP is one tool to prevent the virus, and refers to anti-retroviral medication taken by people who do not have HIV to reduce the risk of contracting it through sexual transmission or injection drug use. These new findings offer immense promise for the future of PrEP as a global tactic to protect young women from contracting HIV.